A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain is a phase 2 interventional study registered as NCT07029737 by AstraZeneca, with 55 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-12-31. Interventions recorded: Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy. Conditions listed: Mantle-cell Lymphoma. No results are recorded here; the registry entry is the source.